| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |